Ting Deng

Ting Deng

Auto-generated profile, based on publicly available information

Ting Deng

State Key Laboratory of Chem/Biosensing and Chemometrics, Chemistry and Chemical Engineering College, Hunan University, Changsha 410082, China

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
TDTing Deng
Ting Deng
QHQidan Huang
Qidan Huang
TWTing Wan
Ting Wan
XLXiaolin Luo
Xiaolin Luo
YFYanling Feng
Yanling Feng
JLJihong Liu
Jihong Liu
Deng T, et al. J Gynecol Oncol. 2021 Mar;32(3):e40. https://doi.org/10.3802/jgo.2021.32.e40

8 May 2019 in Cancer Communications
Verified
Journal Article
Open access
PDF file
ZWZhi‐Qiang Wang
Zhi‐Qiang Wang
RNRuifang Niu
Ruifang Niu
TDTing Deng
Ting Deng
LZLe Zhang
Le Zhang
FFFen Feng
Fen Feng
YLYu-Hong Li
Yu-Hong Li
Background: Oxaliplatin, irinotecan, 5‐fluorouracil, and l ‐leucovorin (FOLFIRINOX) has become one of the first‐line treatment options for advanced pancreatic cancer (PC). However, the relatively high rate of grade 3 or 4 adverse events associated with the standard dosage of FOLFIRINOX limits its widespread use in clinical practice. In this study, we were to evaluate the efficacy and safety of a modified FOLFIRINOX regimen as a first‐line chemotherapy for Chinese patients with metastatic PC. Methods: Patients with histologically confirmed primary metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2 were recruited to receive the modified FOLFIRINOX regimen (intravenous infusion of oxaliplatin, 65 mg/m 2 ; irinotecan, 150 mg/m 2 ; l ‐leucovorin, 200 mg/m 2 ; and 5‐fluorouracil, 2400 mg/m 2 , repeated every 2 weeks). The treatment was continued for 12 cycles unless the patient had progressive disease (PD), stable disease (SD) with symptom deterioration, unacceptable adverse events, or requested to terminate the treatment prematurely. The primary endpoint was objective response rate (ORR). Results: Sixty‐five patients were enrolled from July 2012 to April 2017 in three institutions, and they all received at least one cycle of chemotherapy, with a median of 8 cycles (range 1–12 cycles). No complete response was observed. Twenty‐one (32.3%) patients had partial responses, and 27 (41.5%) had SD. The ORR and disease control rate of the study cohort was 32.3% and 73.8%. The estimated median overall survival and progression‐free survival were 11.60 (95% confidence interval [CI] 8.76–14.44) and 5.77 (95% CI 5.00–6.54) months. Major grade 3 or 4 adverse events included neutropenia (12.3%) and diarrhea (6.2%). No treatment‐related death was observed. Conclusions: Modified FOLFIRINOX was well‐tolerated and might be a promising option as first‐line therapy for Chinese patients with metastatic PC. Trial registration ClinicalTrials.gov , NCT02028806. Registered 7 January 2014, https://clinicaltrials.gov/ct2/show/NCT02028806

1 February 2006 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
TDTing Deng
Ting Deng
JLJi-Shan Li
Ji-Shan Li
SHShuang-Yan Huan
Shuang-Yan Huan
HYHai-Feng Yang
Hai-Feng Yang
HWHua Wang
Hua Wang
RYRu-Qin Yu
Ru-Qin Yu

23 September 2015 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
QTQiao Tang
Qiao Tang
NWNingning Wang
Ningning Wang
FZFulin Zhou
Fulin Zhou
TDTing Deng
Ting Deng
SZSongbai Zhang
Songbai Zhang
WTWeihong Tan
Weihong Tan
In the present study, a novel two-photon nanoprobe has been developed and successfully applied in glutathione (GSH) imaging in cell apoptosis of cancer tissue.

1 January 2007 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
HCHuan Chen
Huan Chen
Jianjhui JiangJianjhui Jiang
Jianjhui Jiang
YLYin-Feng Li
Yin-Feng Li
TDTing Deng
Ting Deng
GSGuo-Li Shen
Guo-Li Shen
RYRu-Qin Yu
Ru-Qin Yu

1 April 2004 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
TDTing Deng
Ting Deng
HWHua Wang
Hua Wang
JLJi-Shan Li
Ji-Shan Li
SHShun-Qin Hu
Shun-Qin Hu
GSGuo-Li Shen
Guo-Li Shen
RYRu-Qin Yu
Ru-Qin Yu